SAN DIEGO, CA--(Marketwired - May 4, 2017) - MyDx, Inc. (OTCQB: MYDX), a science and technology company and
creator of MyDx® (My Diagnostic), the first multi-use handheld
chemical analyzer designed for Cannabis professionals and retail
consumers to correlate the chemical profile of cannabis with how it
makes them feel and which ailments it alleviates, today announced a
new service offering in MyDx360, a Software As A Service
(SAAS)-based community engagement platform designed to help
entrepreneurs develop, launch and track the effects of newly
formulated concetrate products on consumers to help penetrate their
target markets more effectively.
As part of the service, companies will choose from among MyDx's
many chemical formulations that best align with the ailments its
target demographic is seeking to alleviate. From there, MyDx will
outsource the delivery of those formulations through licensed
concentrate manufacturing facilities and provide
customer-engagement support via its SAAS platform to acquire and
analyze user feedback. Collectively, this suite of services will be
called MyDx360.
MyDx360 Overview
- Select Formula: Select from MyDx's
database of targeted formulas and choose an intensity level (Low,
Medium and High). Further customization exists for premium
contracts.
Product Development: MyDx will send your
specifications to one of your preferred concentrate manufacturing
partners.
Customer Feedback: As your brand hits the
market, you'll be able to engage your customer base and collect
feedback via the MyDx App.
Data Analysis: As feedback is accumulated,
MyDx will provide you and your customers insights that can then be
used to fine tune new product development/marketing and sales
strategies.
The purpose of MyDx360 is three-fold:
- Bridge the relationship gap between customers and companies
Facilitate real-time feedback to help companies respond to changing
market trends
Provide soup to nuts coverage of formulated-concentrates
MyDx360: Subscription Pricing &
Services
MyDx360 will offer its customers various levels of support
according to its status level in the subscription agreement. For
instance, standard and premium subscribers will have access to
varying levels of formula customization and data analyses to
support their business and product development
initiatives. Please see attached image for more
details.
"MyDx360 will offer seamless market entry to aspiring
entrepreneurs and brands by streamlining the process by which they
create formulated-concentrates and then provides them with a
feedback ecosystem directly connecting customers with brands", said
Daniel Yazbeck, Chief Executive Officer, MyDx. "It will also
provide MyDx with a new high margin revenue stream where it is able
to leverage its software and data to support the hyper growth in
the market."
For more information regarding MyDx360, please
visit www.cdxlife.com/mydx360 or
email info@cdxlife.com.
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor
technology company based in San Diego, California whose mission is
to help people Trust & Verify® what they put into their minds
and bodies. The Company developed MyDx®, a patented, affordable
portable analyzer that provides real-time chemical analysis and
fits in the palm of the user's hand. The multi-use MyDx analyzer
leverages over a decade of established chemical detection
technology to measure chemicals of interest. The Company owns a
substantial and growing intellectual property portfolio of patents
covering its technology. The MyDx AquaDx®, OrganaDx™ and CannaDx™
sensors are now commercialized, and the AeroDx® application is next
in line. All sensors will be compatible with a MyDx App that
empowers consumers to live a healthier life by revealing the
chemical composition of what they eat, drink and inhale. For more
information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that
term is defined in Section 27(a) of the Securities Act of 1933, as
amended, and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements may contain certain forward-looking
statements pertaining to future anticipated or projected plans,
performance and developments, as well as other statements relating
to future operations and results. Any statements in this press
release that are not statements of historical fact may be
considered to be forward-looking statements. Words such as "may,"
"will," "expect," "believe," "anticipate," "estimate," "intends,"
"goal," "objective," "seek," "attempt," or variations of these or
similar words, identify forward-looking statements. These
forward-looking statements by their nature are estimates of future
results only and involve substantial risks and uncertainties,
including but not limited to risks associated with the uncertainty
of future financial results, additional financing requirements,
development of new products, our ability to complete our product
testing and launch our product commercially, the acceptance of our
product in the marketplace, the uncertainty of the laws and
regulations relating to cannabis, the impact of competitive
products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed from time to time in
our reports filed with the Securities and Exchange Commission,
available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.